BioTelemetry, Inc. (NASDAQ:BEAT)’s share price reached a new 52-week high on Tuesday . The company traded as high as $18.10 and last traded at $17.69, with a volume of 227,088 shares changing hands. The stock had previously closed at $17.50.

Separately, Zacks Investment Research lowered shares of BioTelemetry from a “hold” rating to a “sell” rating in a research report on Tuesday, April 19th.

The company has a 50 day moving average of $16.38 and a 200 day moving average of $13.11. The company has a market cap of $498.05 million and a P/E ratio of 45.203.

BioTelemetry (NASDAQ:BEAT) last released its earnings results on Tuesday, April 26th. The company reported $0.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.10 by $0.10. During the same quarter last year, the company posted $0.06 earnings per share. The business had revenue of $48.60 million for the quarter, compared to analysts’ expectations of $46.54 million. The business’s quarterly revenue was up 12.0% compared to the same quarter last year. Equities research analysts predict that BioTelemetry, Inc. will post $0.71 earnings per share for the current fiscal year.

Several institutional investors have added to or reduced their stakes in the stock. Russell Frank Co boosted its position in BioTelemetry by 58.9% in the fourth quarter. Russell Frank Co now owns 249,457 shares of the company’s stock valued at $2,933,000 after buying an additional 92,455 shares during the period. Teton Advisors Inc. boosted its position in BioTelemetry by 26.3% in the fourth quarter. Teton Advisors Inc. now owns 135,100 shares of the company’s stock valued at $1,578,000 after buying an additional 28,100 shares during the period. Gabelli Funds LLC acquired a new position in BioTelemetry during the fourth quarter valued at approximately $1,190,000. Wells Fargo & Company MN boosted its position in BioTelemetry by 13.6% in the fourth quarter. Wells Fargo & Company MN now owns 994,163 shares of the company’s stock valued at $11,612,000 after buying an additional 119,328 shares during the period. Finally, Royce & Associates LLC boosted its position in BioTelemetry by 102.2% in the fourth quarter. Royce & Associates LLC now owns 606,700 shares of the company’s stock valued at $7,086,000 after buying an additional 306,700 shares during the period.

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.